20/11/2019 12:59 pm Welcome to isteroids.com - BLOG

Wednesday 02, Sep 2009

  Lenalidomide and dexamethasone effectual against multiple myeloma

Posted By
Pin it Share on Tumblr

Lenalidomide and dexamethasone effectual against multiple myeloma The combination of lenalidomide and dexamethasone is effectual against multiple myeloma: this was a fact that was revealed after a study involving 353 patients with myeloma was conducted at 44 centers in the United States and Canada.

The study also found out that pairing a new thalidomide derivative with a steroid can considerably slowdown any further progression of multiple myeloma, which is an incurable bone marrow cancer. It was also revealed that this combination may also prove its worth to prolong lives of patients who have relapsed from previous treatments.

It was remarked by lead author Donna Weber, M.D., Associate Professor in the Department of Lymphoma and Myeloma at The University of Texas M. D. Anderson Cancer Center that a combination of medical drugs may prove to be beneficial in ongoing treatment as a disease may become resistant to one drug.

Monday 29, Jun 2009

  Trials for Low-dose Steroid Treatment prove effective for Bone Marrow Cancer

Posted By
Pin it Share on Tumblr

Trials for Low-dose Steroid Treatment prove effective for Bone Marrow CancerIn a clinical trial that was conducted by the Eastern Cooperative Oncology Group (ECOG) and sponsored by the National Cancer Institute (NCI) and part of the National Institutes of Health, it was revealed that a low dosage regimen of steroids can prove to be an excellent option for treating bone marrow cancer patients rather than persisting for the standard dose of dexamethasone.

The trial revealed that low doses of dexamethasone, a steroid, with lenalidomide can work wonders on patients who are fighting against newly diagnosed multiple myeloma. It was also revealed that the combination of dexamethasone and lenalidomide brought fewer side-effects.

As per noted study chair Vincent Rajkumar, the combination of lenalidomide plus low-dose dexamethasone is extremely positive and truly represents a potential step ahead for treating multiple myeloma.